Drugs / VCAR33
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05984199 | Dec 2023 → May 2025 | acute myeloid leukemia | Vor Biopharma | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-06 | PureTech | Results PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies puretechhealth.com ↗
VCAR33 ALLO demonstrates encouraging biomarker data at lowest dose |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-09-06 | PureTech | PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies puretechhealth.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VCAR33 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05984199 ↗ |
| Modality | Cell therapy | “VCAR33, a donor-derived CD33-directed chimeric antigen receptor T-cell (CAR T) product” PMID 41636724 ↗ Apr 2026 |
| Target | CD33 | “VCAR33, a donor-derived CD33-directed chimeric antigen receptor T-cell (CAR T) product” PMID 41636724 ↗ Apr 2026 |